PMID- 30608620
OWN - NLM
STAT- MEDLINE
DCOM- 20200220
LR  - 20200309
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Print)
IS  - 1462-0324 (Linking)
VI  - 58
IP  - 6
DP  - 2019 Jun 1
TI  - Inhibition of radiographic progression in psoriatic arthritis by adalimumab 
      independent of the control of clinical disease activity.
PG  - 1025-1033
LID - 10.1093/rheumatology/key417 [doi]
AB  - OBJECTIVES: To evaluate the relationship between radiographic progression and 
      disease activity in subjects with PsA treated with adalimumab (ADA) or placebo 
      (PBO) and the impact of concomitant MTX. METHODS: This was a post hoc analysis of 
      the randomized, double-blind, PBO-controlled ADEPT trial. Subjects were 
      categorized according to time-averaged (TA) disease activity (remission, low, 
      moderate or high) based on Disease Activity Score of 28 joints with CRP 
      [DAS28(CRP)], Disease Activity Index for Psoriatic Arthritis (DAPSA) or Psoriatic 
      Arthritis Disease Activity Score (PASDAS), and achievement of minimal disease 
      activity (MDA) at week 24. Radiographic progression was assessed as change in 
      modified total Sharp score (DeltamTSS) from baseline to week 24. The analyses 
      included interaction terms between disease activity and treatment on radiographic 
      progression, comparison of radiographic progression in subjects categorized by 
      disease activity and treatment, and correlation between disease activity and 
      radiographic progression by treatment. RESULTS: The interaction terms for TA 
      disease activity and treatment on DeltamTSS were significant (P = 0.002-0.008). 
      Irrespective of concomitant MTX, DeltamTSS was lower with ADA vs PBO in all disease 
      activity categories. Importantly, even in subjects having moderate or high 
      disease activity or not achieving MDA, DeltamTSS was significantly lower on ADA than 
      PBO (P = 0.05-0.001 for TA-DAPSA, TA-PASDAS and MDA). Correlations between TA 
      disease activity scores and DeltamTSS were moderately positive and significant (P < 
      0.001) with PBO but non-significant with ADA. CONCLUSION: Among subjects with PsA 
      treated with ADA, there was evidence of a 'disconnect' between disease activity 
      and radiographic progression: inhibition of radiographic progression was greater 
      than expected based on control of clinical disease activity alone. MTX had no 
      added effect. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, 
      NCT00646386.
CI  - (c) The Author(s) 2019. Published by Oxford University Press on behalf of the 
      British Society for Rheumatology.
FAU - Landewe, Robert
AU  - Landewe R
AD  - Department of Clinical Immunology and Rheumatology, Amsterdam Rheumatology & 
      Immunology Centre, Amsterdam, The Netherlands.
FAU - Ritchlin, Christopher T
AU  - Ritchlin CT
AD  - Allergy, Immunology & Rheumatology Division, University of Rochester Medical 
      Center, Rochester, NY, USA.
FAU - Aletaha, Daniel
AU  - Aletaha D
AD  - Division of Rheumatology, Department of Internal Medicine, Medical University of 
      Vienna, Vienna, Austria.
FAU - Zhang, Ying
AU  - Zhang Y
AD  - AbbVie Inc., North Chicago, IL, USA.
FAU - Ganz, Fabiana
AU  - Ganz F
AD  - AbbVie AG, Baar, Switzerland.
FAU - Hojnik, Maja
AU  - Hojnik M
AD  - AbbVie, Ljubljana, Slovenia.
FAU - Coates, Laura C
AU  - Coates LC
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, 
      University of Oxford, Oxford, UK.
LA  - eng
SI  - ClinicalTrials.gov/NCT00646386
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Antirheumatic Agents)
RN  - 981Y8SX18M (Bendamustine Hydrochloride)
RN  - FYS6T7F842 (Adalimumab)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adalimumab/*therapeutic use
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Psoriatic/diagnostic imaging/*drug therapy
MH  - Bendamustine Hydrochloride
MH  - Disease Progression
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Female
MH  - Foot Joints/*diagnostic imaging
MH  - Hand Joints/*diagnostic imaging
MH  - Humans
MH  - Male
MH  - Methotrexate/therapeutic use
MH  - Middle Aged
MH  - Radiography
MH  - Young Adult
PMC - PMC6532443
OTO - NOTNLM
OT  - ADEPT
OT  - MTX
OT  - adalimumab
OT  - disconnect
OT  - psoriatic arthritis
OT  - radiographic progression
EDAT- 2019/01/05 06:00
MHDA- 2020/02/23 06:00
PMCR- 2019/01/03
CRDT- 2019/01/05 06:00
PHST- 2018/07/31 00:00 [received]
PHST- 2018/11/03 00:00 [revised]
PHST- 2019/01/05 06:00 [pubmed]
PHST- 2020/02/23 06:00 [medline]
PHST- 2019/01/05 06:00 [entrez]
PHST- 2019/01/03 00:00 [pmc-release]
AID - 5272716 [pii]
AID - key417 [pii]
AID - 10.1093/rheumatology/key417 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2019 Jun 1;58(6):1025-1033. doi: 
      10.1093/rheumatology/key417.